In the last trading session, 10.88 million Navidea Biopharmaceuticals Inc. (AMEX:NAVB) shares changed hands as the company’s beta touched 1.51. With the company’s per share price at $0.11 changed hands at -$0.01 or -5.92% during last session, the market valuation stood at $11.99M. NAVB’s last price was a discount, traded about -218.18% off its 52-week high of $0.35. The share price had its 52-week low at $0.06, which suggests the last value was 45.45% up since then. When we look at Navidea Biopharmaceuticals Inc.’s average trading volume, we note the 10-day average is 6.54 million shares, with the 3-month average coming to 7.41 million.
Analysts gave the Navidea Biopharmaceuticals Inc. (NAVB) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NAVB as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Navidea Biopharmaceuticals Inc.’s EPS for the current quarter is expected to be $0.
Navidea Biopharmaceuticals Inc. (AMEX:NAVB) trade information
Instantly NAVB was in red as seen at the end of in last trading. With action 23.25%, the performance over the past five days has been green. The drop to weekly highs of 0.1450 on Friday, 09/15/23 subtracted -5.92% to the stock’s daily price. The company’s shares are showing year-to-date downside of -46.24%, with the 5-day performance at 23.25% in the green. However, in the 30-day time frame, Navidea Biopharmaceuticals Inc. (AMEX:NAVB) is 17.60% up. Looking at the short shares, we see there were 2.52 million shares sold at short interest cover period of 0.75 days.
The consensus price target for the stock as assigned by Wall Street analysts is $8.00, meaning bulls need an upside of 98.62% from its current market value. According to analyst projections, NAVB’s forecast low is $8.00 with $8.00 as the target high. To hit the forecast high, the stock’s price needs a -7172.73% plunge from its current level, while the stock would need to soar -7172.73% for it to hit the projected low.
Navidea Biopharmaceuticals Inc. (NAVB) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.00%. The 2023 estimates are for Navidea Biopharmaceuticals Inc. earnings to decrease by -39.30%.
Navidea Biopharmaceuticals Inc. is expected to release its next quarterly earnings report in October.
Navidea Biopharmaceuticals Inc. (AMEX:NAVB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 35.43% of Navidea Biopharmaceuticals Inc. shares while 1.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 2.46%. There are 1.59% institutions holding the Navidea Biopharmaceuticals Inc. stock share, with State Street Corporation the top institutional holder. As of Jun 29, 2023, the company held 0.41% of the shares, roughly 0.41 million NAVB shares worth $37972.0.
Allred Capital Management, LLC holds the second largest percentage of outstanding shares, with 0.29% or 0.29 million shares worth $27033.0 as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. With 0.28 million shares estimated at $25437.0 under it, the former controlled 0.28% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.07% of the shares, roughly 68631.0 shares worth around $6314.0.